Archive For: Conference

The Exposure Response Relationship of Enmetazobactam, Combined with Cefepime, is Best Described by f T > C T in a Murine Thigh Infection Model

F. Berhard 1, M. Machacek 1, P. Warn 2, R. Odedra 2, S. Sordello 2, A. Belley 3, P. Knechtle 3

1 LYO-X Allschwil CH; 2 Evotec Cheshire UK; 3 Allecra Therapeutics Saint-Louis FR

ASM-ESCMID Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance • September 3-6, 2019 • Boston, MA.… Read the rest

 

Pharmacodynamic Targets of Enmetazobactam, Combined with Cefepime, against ESBL Producing Isolates of K. pneumoniae in a Murine Thigh Infection Model

P. Warn 1 , R. Odedra 1 , S. Sordello 1 , F. Berhard 2 , M. Machacek 2 , A. Belley 3 , P. Knechtle 3

1 Evotec Cheshire UK; 2 LYO-X Allschwil CH; 3 Allecra Therapeutics Saint Louis FR.  

ASM-ESCMID Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance • September 3-6, 2019 • Boston, MA.… Read the rest

 

ECCMID 2019 in Amsterdam

We will be at ECCMID 2019 with a poster contribution and as an exhibitor. The poster is on a novel cUTI mouse model and the application of PK/PD modelling to derive the required effect in the mouse model that translates to clinical response. We used historical Levofloxacin data to establish this animal-human translation. Visit us at our booth to learn more how we can support your preclinical, translational and clinical program with PK/PD modelling. … Read the rest

 

Poster presentation at PAGE 2018

Systems Pharmacology model of peripheral serotonin production proposing two different synthesis compartments with markedly different release rates into blood. Link to abstract

M. Machacek (1), L. Renaud (1), C. Kohl (2), M. Vercauteren (2), L. Remen (2), R. Welford (2). (1) LYO-X GmbH, Ringstrasse 9, 4123 Allschwil, Switzerland. (2) Idorsia Pharmaceuticals Limited, Hegenheimermattweg 91, 4123 Allschwil, Switzerland… Read the rest

 

12th Basel M&S Seminar: ‘Modelling … AND SIMULATION’

Read the rest

 

ASCO 2016 abstract 2

Population pharmacokinetics of CAP7.1 and the effect on total target lesion size in adult patients with biliary tract cancer. Matthias Machacek, Ulrich-Frank Pape, Ulrich Keilholz, Marianne Sinn, Stefan Kasper, Johannes Meiler, Arndt Vogel, Lothar Mueller, Karel Caca, Jan Kuhlmann, Oswald Burkhard, Victor Rodriguez Laval, Glyn Steventon, Nalan Utku, Holger Jansen; LYO-X GmbH, Allschwil, Switzerland; Department of Internal Medicine, Charité-Universitätsmedizin, Berlin, Germany; Department for Hemato-Oncology, Comprehensive Cancer Center, Charité-University Medicine, Berlin, Germany; Medizinischen Klinik m.S. Hepatologie und Gastroenterologie, Berlin, Georgia; Department of Medical Oncology, West German Cancer Center, University Hospital Essen, Essen, Germany; Hannover Medical School, Hannover, Germany; Onkologie Praxis, Leer, Germany; Klinikum Ludwigsburg, Ludwigsburg, Germany; Department of Medicine II, University Hospital Freiburg, Freiburg, Germany; Onkologie Praxis, Worms, Germany; Instutut für Radiologie, Berlin, Germany; University of Surrey, Surrey, United Kingdom; CellAct, Dortmund, Germany; CellAct Pharma GmbH, Dortmund, Germany. … Read the rest

 

ASCO 2016 abstract 1

Population pharmacokinetics of PQR309, a dual PI3K/mTOR inhibitor in adult patients with advanced solid tumors. Matthias Machacek1, Lionel Renaud1, Sasa Dimitrijevic2, Debora Schmitz2, Elena Ivanova2, Karin Jorga3; 1LYO-X GmbH, Allschwil, Switzerland; 2PIQUR Therapeutics AG, Basel, Switzerland; 3Karin Jorga Life Science Consulting GmbH, Basel, Switzerland. J Clin Oncol 34, 2016 (suppl; abstr e14101).… Read the rest

 

LATSIS Symposium ETH ZURICH on Personalised Medicine

LYO-X is sponsoring the LATSIS Symposium on Personalised Medicine to be held at the ETH Zurich June 27–29 2016. Personalised medicine has a number of quite attractive advantages. Treatments tailored to the individual patient, for example by therapy selection based on diagnostic tools or by individualised dosing, should improve the effect, lower side effects and lower costs by avoiding ineffective treatments. It appears to be an obvious solution given the situation we have today in the health care system. However, despite the advantages most drugs are still developed as a one-fits-all solution without any diagnostic tools.… Read the rest

 

20. PK/PD Expert Meeting

We were very kindly invited to the 20. Pharmacokinetics/Pharmacodynamics Expert Meeting in Berlin April 14th – 16th 2016. It will be a great opportunity to meet the German PKPD experts. There is an attractive agenda including:

  • Systems Pharmacology
    Methods, Applications, Opportunities and Challenges
  • Dose Finding in Phase II for Confirmatory Clinical Trials
    Overview, Methods, Good Practices and Examples
  • PK/PD of Locally Applied Drugs
    Considerations for (Sub-)Cutaneous and Ocular Administration of Pharmaceuticals

Of course we are in the Systems Pharmacology session where we will talk about the “Introduction to Concepts and Methods of Systems Pharmacology”.… Read the rest